New drug combo targets hidden HER2 in breast cancer brain tumors
NCT ID NCT04965064
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a combination of two drugs, neratinib and capecitabine, can help people with HER2-negative breast cancer that has spread to the brain. The study enrolls 22 adults whose tumors show abnormal HER2 activity on a special test. Researchers will measure how long participants live and how long it takes for the cancer to worsen in the brain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
neratinib and capecitabine
What this could lead to
If successful, this could offer a new treatment option for breast cancer patients with brain metastases whose tumors show hidden HER2 activity, potentially improving survival and delaying brain tumor progression.
What could go wrong
This is a small, early-phase trial with only 22 participants, so results may not apply to everyone. The combination of drugs can cause side effects like diarrhea, nausea, and hand-foot syndrome, and the treatment may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rochester
RECRUITINGRochester, New York, 14642, United States
Contact Email: •••••@•••••